Can CYP2D6 poor metabolizer (PM) status be ruled out by a single genotyping assay?

被引：0
|
作者：
Gaedigk, A
Bradford, LD
Leeder, JS
机构：
[1] Childrens Mercy Hosp, Sect Dev Pharmacol & Expt Therapeut, Kansas City, MO 64108 USA
[2] Morehouse Sch Med, Atlanta, GA 30310 USA
来源：
DRUG METABOLISM REVIEWS | 2002年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
303
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [21] Quantification of Antidepressant and Antipsychotic Exposure Increase Caused by CYP2C19 and CYP2D6 Intermediate and Poor Metabolizer Status
    Milosavljevic, Filip
    Bukvic, Nikola
    Pesic, Vesna
    Pavlovic, Zorana
    Miljevic, Cedo
    Molden, Espen
    Ingelman-Sundberg, Magnus
    Jukic, Marin
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 139 - 139
  • [22] Recipient CYP2D6*4 Poor Metabolizer Status Associates with Early Fibrosis Development after Liver Transplantation
    Zimmermann, Tim
    Hoppe-Lotichius, Maria
    Lautem, Anja
    Schuchmann, Marcus
    Otto, Gerd
    LIVER TRANSPLANTATION, 2011, 17 (06) : S234 - S234
  • [23] RECIPIENT CYP2D6*4 POOR METABOLIZER STATUS ASSOCIATES WITH EARLY FIBROSIS DEVELOPMENT AFTER LIVER TRANSPLANTATION
    Zimmermann, T.
    Hoppe-Lotichius, M.
    Koerner, A.
    Lautem, A.
    Heise, M.
    Galle, P. R.
    Otto, G.
    Schuchmann, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S237 - S238
  • [24] Equal contribution of pharmacogenetic phenotype and phenoconversion to functional CYP2D6 metabolizer status
    Scherf-Clavel, M.
    Frantz, A.
    Eckert, A.
    Weber, H.
    Unterecker, S.
    Deckert, J.
    Reif, A.
    Hahn, M.
    PHARMACOPSYCHIATRY, 2024, 57 (02) : 92 - 92
  • [25] Influence of CYP2D6 Metabolizer Status on Risperidone and Paliperidone Tolerability in Children and Adolescents
    Kanu, Amarachi A.
    Johnston, Michelle M.
    Poweleit, Ethan A.
    Vaughn, Samuel E.
    Strawn, Jeffrey R.
    Ramsey, Laura B.
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2024, 34 (01) : 34 - 41
  • [26] A case report of a poor metabolizer of CYP2D6 presented with unusual responses to nortriptyline medication
    Lee, SY
    Ki, CS
    Hong, KS
    Kim, JW
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2004, 19 (05) : 750 - 752
  • [27] The metabolic profiles of endogenous and exogenous substances in a poor metabolizer of humanized CYP2D6 model
    Qian, Jianchang
    Wang, Yahui
    Kong, Qihui
    Chai, Huiyan
    Hu, Haidan
    Chen, Lianguo
    Hu, Lufeng
    Zhang, Qianwen
    Hu, Guoxin
    Chen, Bingbing
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 203
  • [28] Poor CYP2D6 and ultrarapid CYP2C19 metabolizer: Clinical challenge in psychiatric treatment
    Dlugauskas, E.
    Lengvenyte, A.
    Strumila, R.
    Utkus, A.
    EUROPEAN PSYCHIATRY, 2017, 41 : S163 - S163
  • [29] Therapeutic Drug Monitoring of Psychotropics as a Diagnostic Tool for CYP2D6 Poor Metabolizer Phenotype
    Ganesh, Soraya, V
    Beunk, Lianne
    Nikolik, Bojan
    van der Weide, Jan
    Bet, Pierre M.
    THERAPEUTIC DRUG MONITORING, 2021, 43 (05) : 672 - 680
  • [30] Clinical Significance of a CYP2D6 Poor Metabolizer-A Patient With Schizophrenia on Risperidone Treatment
    Bozina, Nada
    Jovanovic, Nikolina
    Lovric, Mila
    Medved, Vesna
    THERAPEUTIC DRUG MONITORING, 2008, 30 (06) : 748 - 751
12345